Ikena Oncology Company Overview
Ikena Oncology
About Ikena Oncology
Ikena Oncology (NASDAQ:IKNA) focuses on discovering and developing innovative cancer treatments. With a keen interest in harnessing the body's immune system and targeted therapies to fight cancer, Ikena is dedicated to advancing a diverse pipeline of therapeutic candidates aimed at addressing unmet medical needs in oncology. Their projects span multiple stages of discovery and development, emphasizing pathways that are critical for cancer cell growth and survival. Ikena aims to provide new hope and solutions for patients struggling with cancer by pushing the boundaries of science and medicine. Their objective is to transform cancer treatment by developing more effective, safer therapies that can improve the lives of patients worldwide.
What is Ikena Oncology known for?
Snapshot
2016
Year founded
43
Employees
Boston, United States
Head office
Loading Map...
Operations
All Locations
Boston, US
Products and/or services of Ikena Oncology
- IK-930, a TEAD inhibitor targeting the Hippo signaling pathway in tumors.
- IK-175, an AHR inhibitor designed for enhancing anti-tumor immunity.
- IK-412, a novel kynurenine-degrading enzyme aiming to modulate the tumor microenvironment.
- Technology platform for discovering and developing targeted oncology therapies focused on previously undruggable targets.
- Collaboration with Merck to explore combination therapies in oncology, integrating their expertise in cancer treatment.
Ikena Oncology executive team
- Dr. Mark Manfredi Ph.D.President, CEO & Director
- Dr. Jotin Marango M.D., Ph.D.COO, CFO, Head of Corporate Development & Treasurer
- Ms. Rebecca CohenSenior VP of Investor Relations, Corporate Strategy & Communication
- Mr. Jeffrey Ecsedy Ph.D.Chief Development Officer
- Mr. Bob LallySenior Vice President of Finance & Operations
- Mr. David Damphousse M.S.Senior Vice President of Clinical Development Operations